Comparison table between hematologic and solid malignancies
| Feature | Hematologic Malignancies | Solid Tumors | Notes / Pharmacy Implications |
|---|---|---|---|
| Definition | Malignancies of blood, bone marrow, lymph, and lymphoid tissues | Malignancies of solid organs (colon, breast, lung, liver, etc.) | Hematologic often systemic at diagnosis; solid tumors usually localized initially |
| Common Examples | Leukemia (AML, ALL, CLL), Lymphoma (Hodgkin, Non-Hodgkin), Multiple Myeloma | Breast, Colon, Lung, Prostate, Pancreas, Ovarian | Guides treatment planning and monitoring |
| Typical Presentation | Cytopenias, fatigue, infections, lymphadenopathy, bleeding | Local mass, organ-specific symptoms, pain, obstruction, bleeding | Hematologic signs often systemic; solid tumors often organ-specific |
| Diagnosis | CBC, peripheral smear, bone marrow biopsy, flow cytometry, cytogenetics, molecular testing | Imaging (CT, MRI, PET), biopsy, tumor markers (CEA, CA19-9, PSA), molecular testing | Lab monitoring more intensive for hematologic malignancies |
| Staging | Often based on bone marrow involvement, cytogenetics, risk scores (e.g., Rai, FAB, IPSS) | TNM (Tumor, Node, Metastasis), AJCC staging | Staging affects treatment intensity and regimen choice |
| Molecular / Targeted Testing | BCR-ABL, FLT3, NPM1, JAK2, TP53, CD20, CD19 | KRAS/NRAS/BRAF, HER2, EGFR, MMR/MSI, PD-L1 | Guides targeted therapy selection in both settings |
| First-Line Therapy | Often systemic therapy (chemo, targeted agents, immunotherapy) upfront | Surgery if localized, often followed by chemo/radiation; metastatic → systemic therapy | Hematologic rarely curative with surgery alone; solid tumors may be surgically curable |
| Common Regimens | AML: Cytarabine + anthracycline; ALL: Hyper-CVAD; CLL: BTK inhibitors; MM: VRd | CRC: FOLFOX/FOLFIRI; Breast: AC-T; NSCLC: Platinum-based ± targeted | Important for dosing, toxicity monitoring, and drug interactions |
| Route of Administration | Mostly IV, some oral targeted agents | IV, oral, occasionally intraperitoneal (e.g., ovarian) | Oral adherence more critical in targeted therapies |
| Adverse Effect Profile | Myelosuppression, infection risk, bleeding, tumor lysis syndrome, mucositis | Organ-specific toxicities (neuropathy, cardiotoxicity, nephrotoxicity), myelosuppression, hand-foot syndrome, mucositis | Hematologic toxicity often more acute and life-threatening |
| Supportive Care Considerations | Growth factors (G-CSF), transfusions, infection prophylaxis, tumor lysis prophylaxis | Anti-emetics, hydration, growth factors if myelosuppressive, pain management | Hematologic malignancies require more intensive inpatient monitoring |
| Role of Immunotherapy | CAR-T cells, monoclonal antibodies (CD19, CD20), checkpoint inhibitors in select lymphomas | Checkpoint inhibitors (PD-1/PD-L1) for MSI-H, melanoma, NSCLC, RCC | Pharmacist monitoring for cytokine release syndrome (hematologic) vs immune-related adverse events (solid) |
| Surveillance / Follow-Up | CBC, bone marrow exams, minimal residual disease testing, molecular markers | Imaging, tumor markers, physical exams, symptom assessment | Hematologic requires lab-based monitoring; solid tumors focus on imaging and recurrence detection |
| Curability | Often curable with allogeneic stem cell transplant in selected cases | Curable if localized and resectable; metastatic disease generally palliative | Curative potential differs substantially; impacts pharmacy counseling |